XERI
Xeriant, Inc.0.0100
-0.0010-9.09%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
7.90MP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
10-Q
Q2 FY2026 results
Xeriant trimmed operating expenses 31% y/y to $231K in Q2 FY2026 ended December 31, 2025, narrowing its operating loss to $231K from $336K while R&D ticked up modestly on NEXBOARD testing. YTD operating loss shrank 23% y/y to $535K, but swung to net income of $1.9M on a $2.7M gain from extinguishing the Auctus note via October 2025 settlement (30M shares plus $3.5M cash liability). Cash rose to $77K on $415K bridge notes, yet ops burned $383K YTD. Debt sits at $1.7M net (10% notes). Ongoing XTI litigation poses funding risk.
10-Q
Q1 FY2026 results
Xeriant swung to net income of $2.2M for Q1 FY2026 ended September 30, 2025, from a $0.4M loss y/y, driven by a $2.7M gain on extinguishment of the Auctus debt while operating loss narrowed 15% to $304k on lower consulting fees. Cash ticked up to $52k q/q, funded by $185k in new convertible notes, yet operating cash burn hit $178k. Debt restructuring booked a $3.5M settlement liability. Shares outstanding jumped to 749M. Ongoing XTI litigation poses execution risk.
8-K
Xeriant settles Auctus note dispute
Xeriant settled its dispute with Auctus over a $6.05M 2021 note, issuing 30M common shares and committing to $3.5M cash payments staggered through mid-2026 from October 29 effective date. Auctus suspends further conversions if paid timely, returns two 25M-share warrants, but keeps its 51M-share warrant. Litigation proceeds from XTI suit go first to Auctus. Payments avert default.
10-K
FY2025 results
Xeriant posted a narrower FY2025 net loss of $1.6M versus $3.1M in FY2024, driven by slashed operating expenses to $1.4M from $1.9M as R&D dropped to $69K from $196K amid NEXBOARD testing. No revenue yet; cash dwindled to $45K from $653K after $682K in convertible notes raised but $1.3M burned in operations. Ongoing Auctus note battles and XTI litigation cloud the horizon. Losses persist. Debt overhangs liquidity.
10-Q
Q3 FY2025 results
Xeriant narrowed its Q3 FY2025 net loss to $530K from $384K a year earlier, while YTD through March 31, 2025, the loss shrank to $1.3M from $1.9M, driven by lower research costs and no repeat of prior default interest hits. Operating expenses climbed 30% y/y to $459K in the quarter, fueled by advisory fees for new nanomaterials experts, yet R&D dropped sharply as testing wrapped up. Cash dwindled to $54K after $1.1M YTD burn, offset by $517K in convertible notes; total debt stands at $7.6M, including a $5.9M defaulted senior note. Ongoing litigation with XTI Aircraft over a terminated JV could yield upside but drags resources. Litigation clouds the runway.
ACHR
Archer Aviation Inc.
7.95+0.12
AVAV
AeroVironment, Inc.
234.65-0.67
ERJ
Embraer S.A.
64.48-0.74
EVTL
Vertical Aerospace Ltd.
5.69+0.10
HOVR
New Horizon Aircraft Ltd.
1.76+0.16
HXL
Hexcel Corporation
72.31-1.39
LILMF
Lilium N.V.
0.00-0.00
MNTS
Momentus Inc.
0.52+0.06
PKE
Park Aerospace Corp.
20.67-0.08
XTIA
XTI Aerospace, Inc.
1.32-0.04